BTC Capital Management Inc. Acquires 1,455 Shares of Amgen Inc. $AMGN

BTC Capital Management Inc. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 21.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,267 shares of the medical research company’s stock after acquiring an additional 1,455 shares during the quarter. BTC Capital Management Inc.’s holdings in Amgen were worth $2,909,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. High Note Wealth LLC grew its holdings in shares of Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC boosted its position in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after buying an additional 28 shares during the period. Destination Wealth Management boosted its position in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after buying an additional 29 shares during the period. Finally, West Family Investments Inc. boosted its position in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after buying an additional 30 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $351.64 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average price of $340.45 and a 200-day moving average price of $345.95. The company has a market cap of $189.78 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 3.48 and a beta of 0.42. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AMGN. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Morgan Stanley lifted their price target on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 9th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Finally, UBS Group increased their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $354.42.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.